Hua Medicine Ltd., of Shanghai, said it closed a combined series D and series E financing of $117.4 million, which is expected to fully fund the company through completion of its two phase III trials and commercial launch in China for dorzagliatin (HMS-5552), a fourth-generation glucokinase activator that treats the impaired blood glucose sensor function, addressing the underlying cause of type 2 diabetes.